Literature DB >> 23246061

Surgical outcomes after cardiac surgery in liver transplant recipients.

Takeyoshi Ota1, Rodolfo Rocha1, Lawrence M Wei1, Yoshiya Toyoda1, Thomas G Gleason1, Christian Bermudez2.   

Abstract

OBJECTIVE: This was a single-center retrospective study to assess the surgical outcomes and predictors of mortality of liver transplant recipients undergoing cardiac surgery.
METHODS: From 2000 to 2010, 61 patients with a functioning liver allograft underwent cardiac surgery. The mean interval between liver transplantation and cardiac surgery was 5.4 ± 4.4 years. Of the 61 patients, 33 (54%) were in Child-Pugh class A and 28 in class B. The preoperative and postoperative data were reviewed.
RESULTS: The overall in-hospital mortality was 6.6%. The survival rate was 82.4% ± 5.1% at 1 year and 50.2% ± 8.2% at 5 years. Cox regression analysis identified preoperative encephalopathy (odds ratio, 5.2; 95% confidence interval, 1.8-15.5; P = .003) and pulmonary hypertension (odds ratio, 3.5; 95% confidence interval, 1.3-9.4; P = .045) as independent predictors of late mortality. The preoperative Model for End-Stage Liver Disease (MELD) scores of patients who died in-hospital or late postoperatively were significantly greater statistically than the scores of the others (in-hospital death, 23.7 ± 7.8 vs 13.1 ± 4.5, P < .001; late death, 15.2 ± 6.1 vs 12.3 ± 4.1, P = .038). The Youden index identified an optimal MELD score cutoff value of 13.5 (sensitivity, 56.0%; specificity, 67.6%). Kaplan-Meier survival analysis successfully demonstrated that the survival rate of the MELD score less than 13.5 (MELD <13.5) group was significantly greater than that of the MELD >13.5 group (MELD <13.5 group, 93.8% ± 4.2% at 1 year and 52.4% ± 11.8% at 5 years; MELD >13.5 group, 66.9% ± 9.6% at 1 year and 46.1% ± 11.1% at 5 years; P = .027). In contrast, the survival rate when stratified by Child-Pugh class (class A vs B) was not significantly different.
CONCLUSIONS: Cardiac surgery in the liver allograft recipients was associated with acceptable surgical outcomes. Preoperative encephalopathy and pulmonary hypertension were independent predictors of late mortality. The cutoff value of 13.5 in the MELD score might be useful for predicting surgical mortality in cardiac surgery.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23246061     DOI: 10.1016/j.jtcvs.2012.09.099

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Liver dysfunction as an important predicting risk factor in patients undergoing cardiac surgery: a systematic review and meta-analysis.

Authors:  Wan Chin Hsieh; Po Chen Chen; Flavia-Catalina Corciova; Grigore Tinica
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Outcomes and risk factors of postoperative hepatic dysfunction in patients undergoing acute type A aortic dissection surgery.

Authors:  Wei Zhou; Guokun Wang; Yaoyang Liu; Yun Tao; Zhen Du; Yangfeng Tang; Fan Qiao; Yang Liu; Zhiyun Xu
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 3.  Surgical Outcome of Cerebral Aneurysm Clipping Treated with Immunosuppressants: Report of 11 Cases and Review of the Literature.

Authors:  Masaaki Hokari; Naoki Nakayama; Ken Kazumata; Toshiya Osanai; Hideo Shichinohe; Takeo Abumiya; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-01-31       Impact factor: 1.742

4.  Coil Embolization for a Cerebral Aneurysm in a Heart Transplantation Patient: A Case Report.

Authors:  Masatoshi Takagaki; Tomoyoshi Nakagawa; Shuhei Kawabata; Nobuyuki Izutsu; Takeo Nishida; Hajime Nakamura; Haruhiko Kishima
Journal:  NMC Case Rep J       Date:  2019-12-18

5.  Aortic valve-sparing procedure-a durable choice in liver transplantation recipient.

Authors:  Andrea De Martino; Stefano Pratali; Paola Carrai; Stefania Petruccelli; Paolo De Simone; Uberto Bortolotti
Journal:  Gen Thorac Cardiovasc Surg       Date:  2020-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.